SG11202103965TA - Cyclodextrin-based formulation of a bcl-2 inhibitor - Google Patents
Cyclodextrin-based formulation of a bcl-2 inhibitorInfo
- Publication number
- SG11202103965TA SG11202103965TA SG11202103965TA SG11202103965TA SG11202103965TA SG 11202103965T A SG11202103965T A SG 11202103965TA SG 11202103965T A SG11202103965T A SG 11202103965TA SG 11202103965T A SG11202103965T A SG 11202103965TA SG 11202103965T A SG11202103965T A SG 11202103965TA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl
- cyclodextrin
- inhibitor
- based formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753164P | 2018-10-31 | 2018-10-31 | |
| PCT/EP2019/079644 WO2020089286A1 (en) | 2018-10-31 | 2019-10-30 | Cyclodextrin-based formulation of a bcl-2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103965TA true SG11202103965TA (en) | 2021-05-28 |
Family
ID=68536777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103965TA SG11202103965TA (en) | 2018-10-31 | 2019-10-30 | Cyclodextrin-based formulation of a bcl-2 inhibitor |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20210353633A1 (zh) |
| EP (1) | EP3873529A1 (zh) |
| JP (1) | JP2022506069A (zh) |
| KR (1) | KR20210102886A (zh) |
| CN (1) | CN112912108A (zh) |
| AR (1) | AR116922A1 (zh) |
| AU (1) | AU2019373373B2 (zh) |
| BR (1) | BR112021007987A2 (zh) |
| CA (1) | CA3117511A1 (zh) |
| CL (1) | CL2021001018A1 (zh) |
| CO (1) | CO2021005221A2 (zh) |
| CR (1) | CR20210210A (zh) |
| DO (1) | DOP2021000073A (zh) |
| EA (1) | EA202191144A1 (zh) |
| GE (1) | GEP20237580B (zh) |
| IL (1) | IL282688A (zh) |
| JO (1) | JOP20210079A1 (zh) |
| MX (1) | MX2021004864A (zh) |
| NI (1) | NI202100031A (zh) |
| PE (1) | PE20211738A1 (zh) |
| PH (1) | PH12021550878A1 (zh) |
| SG (1) | SG11202103965TA (zh) |
| TW (1) | TWI738100B (zh) |
| UY (1) | UY38431A (zh) |
| WO (1) | WO2020089286A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4188387A1 (en) | 2020-07-31 | 2023-06-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof |
| WO2022090443A1 (en) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor |
| JP2024511422A (ja) | 2021-03-24 | 2024-03-13 | レ ラボラトワール セルヴィエ | ５－｛５－クロロ－２－［（３ｓ）－３－［（モルホリン－４－イル）メチル］－３，４－ジヒドロイソキノリン－２（１ｈ）－カルボニル］フェニル｝－１，２－ジメチル－１ｈ－ピロール－３－カルボン酸誘導体を合成するための新規な製造方法及び医薬化合物を製造するためのその適用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996041646A2 (en) * | 1995-06-13 | 1996-12-27 | Dyer, Alison, Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
| JP2003321364A (ja) * | 2002-05-07 | 2003-11-11 | Eisai Co Ltd | シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物 |
| WO2014108918A2 (en) * | 2013-01-08 | 2014-07-17 | Mylan Laboratories Limited | An injectable antifungal formulation |
| FR3008975A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20200054639A1 (en) * | 2016-10-31 | 2020-02-20 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
-
2019
- 2019-10-29 UY UY0001038431A patent/UY38431A/es unknown
- 2019-10-30 GE GEAP201915618A patent/GEP20237580B/en unknown
- 2019-10-30 AR ARP190103144A patent/AR116922A1/es unknown
- 2019-10-30 KR KR1020217016354A patent/KR20210102886A/ko active Search and Examination
- 2019-10-30 SG SG11202103965TA patent/SG11202103965TA/en unknown
- 2019-10-30 EA EA202191144A patent/EA202191144A1/ru unknown
- 2019-10-30 BR BR112021007987-4A patent/BR112021007987A2/pt unknown
- 2019-10-30 CA CA3117511A patent/CA3117511A1/en active Pending
- 2019-10-30 JO JOP/2021/0079A patent/JOP20210079A1/ar unknown
- 2019-10-30 WO PCT/EP2019/079644 patent/WO2020089286A1/en active Application Filing
- 2019-10-30 EP EP19801728.7A patent/EP3873529A1/en active Pending
- 2019-10-30 MX MX2021004864A patent/MX2021004864A/es unknown
- 2019-10-30 CN CN201980070474.4A patent/CN112912108A/zh active Pending
- 2019-10-30 US US17/288,721 patent/US20210353633A1/en active Pending
- 2019-10-30 TW TW108139349A patent/TWI738100B/zh active
- 2019-10-30 PE PE2021000642A patent/PE20211738A1/es unknown
- 2019-10-30 AU AU2019373373A patent/AU2019373373B2/en active Active
- 2019-10-30 CR CR20210210A patent/CR20210210A/es unknown
- 2019-10-30 JP JP2021523227A patent/JP2022506069A/ja active Pending
-
2021
- 2021-04-20 PH PH12021550878A patent/PH12021550878A1/en unknown
- 2021-04-21 DO DO2021000073A patent/DOP2021000073A/es unknown
- 2021-04-21 CL CL2021001018A patent/CL2021001018A1/es unknown
- 2021-04-23 CO CONC2021/0005221A patent/CO2021005221A2/es unknown
- 2021-04-27 IL IL282688A patent/IL282688A/en unknown
- 2021-04-29 NI NI202100031A patent/NI202100031A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873529A1 (en) | 2021-09-08 |
| TW202031295A (zh) | 2020-09-01 |
| CA3117511A1 (en) | 2020-05-07 |
| PH12021550878A1 (en) | 2021-10-18 |
| AU2019373373A1 (en) | 2021-05-20 |
| WO2020089286A1 (en) | 2020-05-07 |
| KR20210102886A (ko) | 2021-08-20 |
| CO2021005221A2 (es) | 2021-07-19 |
| CR20210210A (es) | 2021-05-25 |
| CL2021001018A1 (es) | 2021-11-26 |
| BR112021007987A2 (pt) | 2021-08-03 |
| MX2021004864A (es) | 2021-08-11 |
| JOP20210079A1 (ar) | 2023-01-30 |
| US20210353633A1 (en) | 2021-11-18 |
| AR116922A1 (es) | 2021-06-30 |
| JP2022506069A (ja) | 2022-01-17 |
| GEP20237580B (en) | 2023-12-25 |
| UY38431A (es) | 2020-05-29 |
| NI202100031A (es) | 2021-08-24 |
| TWI738100B (zh) | 2021-09-01 |
| AU2019373373B2 (en) | 2023-09-28 |
| PE20211738A1 (es) | 2021-09-06 |
| IL282688A (en) | 2021-06-30 |
| DOP2021000073A (es) | 2021-11-15 |
| CN112912108A (zh) | 2021-06-04 |
| EA202191144A1 (ru) | 2021-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3788042A4 (en) | BCL-2 INHIBITORS | |
| IL292642A (en) | ras inhibitors | |
| IL292643A (en) | ras inhibitors | |
| IL292644A (en) | ras inhibitors | |
| EP3626699A4 (en) | SSAO INHIBITOR | |
| EP3801503A4 (en) | INHIBITORS OF SARM1 | |
| IL282688A (en) | A cyclodextrin-based formulation of a BCL-2 inhibitor | |
| EP3906029A4 (en) | INHIBITORS OF MENIN-MLL INTERACTION | |
| EP4051676A4 (en) | BCL-2 INHIBITORS | |
| IL277778B (en) | inhibitors of bcl6 | |
| EP3347333A4 (en) | USE OF POLYMERIZATION INHIBITOR COMPOSITIONS | |
| EP3681499A4 (en) | CONNECTIONS AS RAS INHIBITORS AND THEIR USE | |
| EP3595658A4 (en) | FORMS AND COMPOSITIONS OF A MK2 INHIBITOR | |
| EP3765619A4 (en) | INHIBITORS OF MICRO-RNA 22 | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| EP3801499A4 (en) | INHIBITORS OF SARM1 | |
| EP3712147B8 (en) | Sglts inhibitor and application thereof | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION, INCLUDING PDE9 INHIBITOR | |
| EP3801500A4 (en) | INHIBITORS OF SARM1 | |
| ZA202103580B (en) | Aminopeptidase a inhibitors and pharmaceutical compositions comprising the same | |
| IL289620A (en) | Nanoparticle formulation of bcl-2 inhibitor | |
| EP3801525A4 (en) | PROLYL-ARNT-SYNTHETASE INHIBITORS | |
| EP3814324A4 (en) | CATHEPSIN-C HEMMER | |
| EP3774708A4 (en) | Foxm1 inhibitor compositions and methods of using the same | |
| EP3687514A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITION OF STAT3 |